Core Insights - Zacks Premium offers various tools for investors to enhance their stock market engagement and confidence, including daily updates, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum characteristics, helping investors identify stocks likely to outperform the market in the short term [2][3] - Each stock receives a rating from A to F, with A indicating the highest potential for outperformance [3] Value Score - The Value Style Score identifies attractive stocks based on valuation ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow, appealing to value investors [3] Growth Score - The Growth Style Score focuses on a company's future prospects and financial health, analyzing projected and historical earnings, sales, and cash flow to find sustainable growth stocks [4] Momentum Score - The Momentum Style Score helps investors capitalize on price trends, using metrics like one-week price changes and monthly earnings estimate changes to identify optimal entry points [5] VGM Score - The VGM Score combines the three Style Scores, providing a comprehensive rating that highlights stocks with strong value, growth potential, and positive momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to assist investors in building successful portfolios, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.83% since 1988, outperforming the S&P 500 [7][8] - There are typically over 800 top-rated stocks available, making it essential for investors to utilize Style Scores for better selection [9] Stock to Watch: Incyte Corporation - Incyte Corporation, a biopharmaceutical company, is currently rated 3 (Hold) on the Zacks Rank and has a VGM Score of A, indicating solid potential [12] - The company has a Value Style Score of B, supported by a forward P/E ratio of 14, making it attractive to value investors [13] - Recent analyst revisions have increased earnings estimates for fiscal 2025, with the Zacks Consensus Estimate rising to $6.87 per share and an average earnings surprise of +14.4%, positioning Incyte as a noteworthy investment opportunity [13]

Core Viewpoint - Incyte Corporation (INCY) is expected to exceed revenue and earnings estimates for Q4 2025, with projected revenues of $1.35 billion and earnings of $1.94 per share [2][6]. Revenue Drivers - The primary revenue source for Incyte is the sales of its lead drug, Jakafi (ruxolitinib), which is anticipated to continue its strong performance across all approved indications [3][4]. - Jakafi's fourth-quarter sales are estimated at $799.3 million, with additional royalty revenues expected from Novartis due to higher Jakavi sales outside the U.S. [4][6]. - Other contributing factors to revenue include growth in Opzelura sales, which are projected at $196.5 million, and sales from other drugs like Minjuvi, Pemazyre, and Iclusig [8][12]. Recent Developments - Incyte's recent approval of Monjuvi for a new cancer indication is likely to enhance its sales, with the drug also receiving approval in the EU and Japan [10][12]. - The launch of Niktimvo, which recorded $45.8 million in sales in Q3 2025, is another significant development for the company [13][14]. Financial Performance - Incyte's stock has increased by 31.4% over the past six months, compared to the industry growth of 43.5% [5]. - The company has a mixed earnings surprise history, beating estimates in three of the last four quarters with an average surprise of 14.35% [15]. Earnings Expectations - The Earnings Surprise Prediction model indicates a likelihood of an earnings beat for Incyte, with an Earnings ESP of +3.69% [16][17].

Core Insights - The report summarizes significant analyst rating adjustments that could influence market trends, highlighting both upgrades and downgrades across various companies [1]. Upgrades - B. Riley upgraded Snap (SNAP) from Neutral to Buy, maintaining a target price of $10, citing strong growth in high-end subscription revenue and the rollout of high-margin advertising formats [5]. - Seaport Research upgraded FuboTV (FUBO) from Neutral to Buy with a target price of $3, viewing current uncertainties as a quality investment opportunity following a significant stock drop post-earnings [5]. - Wolfe Research upgraded Zoom Video Communications (ZM) from Peer Perform to Outperform, setting a target price of $115, anticipating a re-acceleration in growth and strong performance in its contract center and phone business [5]. - Jefferies upgraded Celanese (CE) from Hold to Buy, raising the target price from $43 to $86, suggesting it is a good time to buy despite potential earnings volatility in the first half of 2026 [5]. - Cantor Fitzgerald upgraded DigitalOcean (DOCN) from Neutral to Overweight, increasing the target price from $47 to $68, emphasizing its focus on digital-native enterprises and a strong foundation for market expansion [5]. Downgrades - Stifel downgraded Microsoft (MSFT) from Buy to Hold, reducing the target price from $540 to $392, citing supply issues with Azure and strong competition from Google Cloud [5]. - Susquehanna downgraded Qualcomm (QCOM) from Positive to Neutral, lowering the target price from $210 to $140, recommending a wait-and-see approach due to industry challenges [5]. - Citigroup downgraded Six Flags Entertainment (FUN) from Buy to Neutral, cutting the target price from $25 to $20, citing overvaluation after a 40% increase since November [5]. - Jefferies downgraded Steven Madden (SHOO) from Hold to Underperform, lowering the target price from $37 to $30, highlighting ongoing pressures in its wholesale business [5]. - JPMorgan downgraded Corteva (CTVA) from Overweight to Neutral, raising the target price from $75 to $77, based on valuation considerations [5]. Initiations - Benchmark initiated coverage on Cava Group (CAVA) with a Buy rating and a target price of $80, recognizing its leading position in the Mediterranean dining category [5]. - H.C. Wainwright initiated coverage on Incyte (INCY) with a Buy rating and a target price of $135, noting potential catalysts that could stabilize revenue expectations post-Jakafi patent expiration [5]. - Bernstein initiated coverage on Coupang (CPNG) with an Underperform rating and a target price of $17, favoring companies with strong growth potential driven by online penetration [5]. - Benchmark initiated coverage on Andersons (ANDE) with a Buy rating and a target price of $75, highlighting the growth momentum in its ethanol business [5]. - Bank of America initiated coverage on Wave Life Sciences (WVE) with a Buy rating and a target price of $38, emphasizing the differentiated advantages of its obesity drug WVE-007 [6].

Incyte Corporation (NASDAQ:INCY) is one of the most undervalued quality stocks to buy right now. On January 13, TD Cowen raised its price target for Incyte to $128 from $101 with a Buy rating on the shares. The firm’s optimism follows Incyte’s presentation of a strategic roadmap aimed at potentially tripling its revenue, excluding Jakafi, by 2029. With several Phase 3 trial readouts and initiations scheduled, the firm views 2026 as a pivotal year for both execution and delivery for the company. Furthermo ...

Incyte Corp (NASDAQ:INCY) is one of the most undervalued stocks to buy and hold for 5 years. On January 27, Bank of America Securities analyst Tazeen Ahmad assigned a Buy rating to Incyte and set a $118 price target. This bullish ratings action stands in contrast to Wells Fargo’s downgrade of Incyte Corp (NASDAQ:INCY) to Equal Weight from Overweight on January 20. According to Wells Fargo, which also lowered the stock’s price target to $107 from $116, the downgrade reflects the company’s current valuation a ...

Core Opinion - The article highlights the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding Zynyz® (retifanlimab) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC) [1] Company Summary - The company, Incyte, is advancing its product Zynyz® (retifanlimab) in the oncology space, specifically targeting advanced SCAC [1] Industry Context - The approval of Zynyz® could potentially impact treatment options in the oncology market, particularly for patients with advanced SCAC, indicating a significant development in cancer therapeutics [1]

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1][2] Zacks Style Scores - Zacks Style Scores rate stocks based on value, growth, and momentum, serving as complementary indicators to the Zacks Rank [3] - Stocks receive an alphabetic rating from A to F, with A indicating the highest potential for outperforming the market [4] Value Score - The Value Style Score focuses on identifying undervalued stocks using ratios like P/E, PEG, and Price/Sales [4] Growth Score - The Growth Style Score evaluates stocks based on projected and historical earnings, sales, and cash flow to identify sustainable growth opportunities [5] Momentum Score - The Momentum Style Score assesses stocks based on price trends and earnings outlook changes, helping investors capitalize on upward or downward price movements [6] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investing strategies [7] Zacks Rank and Style Scores - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in portfolio creation [8] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [9] Stock Selection Strategy - For optimal returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [10] - Stocks with a 3 (Hold) rank should also have Style Scores of A or B to maximize upside potential [10] Company Spotlight: Incyte Corporation - Incyte Corporation, based in Wilmington, DE, is a biopharmaceutical company engaged in developing proprietary therapeutics [12] - Currently rated 3 (Hold) with a VGM Score of A, Incyte has a Momentum Style Score of A and has seen a 1.9% increase in shares over the past four weeks [12][13] - The earnings estimate for fiscal 2025 has been revised upwards, with the Zacks Consensus Estimate now at $6.88 per share, reflecting an average earnings surprise of +14.4% [13]

Core Viewpoint - The article reflects a personal journey of an individual with a background in engineering who has developed a strong interest in investing, particularly in technology stocks, over the past 15 years [1]. Group 1 - The individual has over 30 years of experience as a Merchant Seaman, which has contributed to a global perspective [1]. - The interest in investing was significantly influenced by resources from The Motley Fool [1]. - The individual currently holds no stock, options, or similar derivative positions in any mentioned companies and has no plans to initiate any such positions in the near future [1].

Group 1 - The article does not provide any specific content related to company or industry analysis [1]

Core Insights - The article highlights the professional background of Brendan, who has extensive experience in the pharmaceutical and biotechnology sectors, including a Ph.D. in organic synthesis from Stanford University and significant roles at major companies like Merck and 1200 Pharma [1] Group 1: Professional Background - Brendan completed a Ph.D. at Stanford University in organic synthesis in 2009 [1] - He worked for Merck from 2009 to 2013, gaining experience in a major pharmaceutical company [1] - Brendan has been involved in biotech startups, including Theravance and Aspira, before joining Caltech [1] Group 2: Entrepreneurial Ventures - He was the first employee and co-founder of 1200 Pharma, which spun out of Caltech and secured major investments in the eight-figure range [1] - Brendan remains an avid investor, focusing on market trends, particularly in biotechnology stocks [1]